Summary & Overview
HCPCS J1961: Injection, Lenacapavir for HIV Treatment, 1 mg
HCPCS Level II code J1961 designates lenacapavir as an injectable agent for HIV treatment, billed per 1 mg. Lenacapavir is a long-acting antiretroviral formulation used in specialist and clinic-based settings, making the code important for practices that provide injectable HIV therapies and for payers managing specialty drug spend. Nationally, accurate coding of J1961 affects claim adjudication, specialty pharmacy billing, and access to long-acting HIV treatment options.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage patterns and where available, benchmark approaches to reimbursement for injectable antiretrovirals.
Readers will find concise benchmarks, clinical context for use of lenacapavir injections, and policy-related updates relevant to billing and coverage for specialty injectable HIV therapies. The report summarizes common billing considerations for clinic and infusion settings, highlights national payer approaches, and provides clarity on how J1961 is represented in service lines for outpatient administration. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J1961 is for injection, lenacapavir (only for use as hiv treatment), 1 mg. This code represents the drug product used specifically for the treatment of human immunodeficiency virus (HIV).
Service type: Drug administration (injectable antiviral therapy)
Typical site of service: Outpatient clinic, infusion center, or clinic-based injection setting
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with multidrug-resistant HIV-1 infection receiving long-acting injectable antiretroviral therapy. The medication J1961 (lenacapavir, 1 mg units) is administered by a trained clinician in an outpatient infusion clinic, HIV clinic, or specialty pharmacy clinic. The workflow includes medication reconciliation, confirmation of current antiretroviral regimen and resistance profile, verification of dosing schedule (induction subcutaneous or maintenance subcutaneous every two months as clinically indicated), informed consent for injection therapy, medication preparation and dose calculation (multiple milligrams per dose using J1961 units), subcutaneous injection in the abdomen or buttock, monitoring for immediate adverse reactions for 15–30 minutes, documentation of lot number and units billed, and scheduling of the next administration. Typical sites of service are outpatient infusion center, physician office, or ambulatory clinic. Patient counseling covers injection site reactions, signs of hypersensitivity, adherence to concurrent oral antiretrovirals if required, and instructions to contact their HIV care team for systemic symptoms.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard reporting | Use when no special circumstance modifier applies to the service. |